AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study
BenzingaAugust 21, 2019, 1:04 PM UTC. AstraZeneca plc (NYSE: AZN) faced a clinical setback in a study evaluating a combo drug regimen in non-small cell lung cancer, or NSCLC. AstraZeneca said a Phase 3 study dubbed NEPTUNE that evaluated its PD-LI inhibitor Imfinzi in combination with tremelimumab, an anti-CTLA4 antibody, versus platinum-based chemotherapy – the current standard-of-care- in previously untreated Stage IV NSCLC did not meet the primary endpoint of improving overall survival. The company noted that the primary analysis population was patients with a high tumor mutational burden. The safety and tolerability profile of the combo, however, was consistent with previous trials. AstraZeneca said it intends to do a deep analysis of the vast clinical and biomarker data from the trial to gain further insights to improve Immuno-oncology approaches for patients with metastatic NSCLC. Imfinzi is also being tested as monotherapy in a Phase 3 trial, dubbed PEARL, and in combination with chemotherapy with or without tremelimumab in the Phase 3 trial, dubbed POSEIDON, as part of an extensive late-stage Immuno-oncology program in Stage IV NSCLC.